Cancer-treatment drug Nexavar will soon be available to patients at Rs. 8,880 a pack of 120 tablets, thanks to India invoking an international trade rule allowing the generic production of an unaffordable drug that is patented.
Bayer, a German multi-national, holds the patent for Nexavar (the brand name of sorafenib tosylate), which now sells at Rs.2.84 lakh.
The drug is used for the treatment at the advanced stages of kidney and liver cancer. The drug stops the growth of new blood vessels and targets other important cellular growth factors. Though it is not a life-saving drug, it is a life- extending drug. In the case of kidney cancer, it can extend the life of a patient by four-five years, while in the case of liver cancer it can extend life by about six- eight months.http://www.thehindu.com/news/national/a ... 988811.ece